Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer - sprookjes - yvandenbroek - TriplyDB

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

http://www.wikidata.org/entity/Q34268618

about

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.

P2860

Q28067145-1907FDEE-F5FB-4B90-B786-D34AA5E603CE Q33688821-1C19FE09-D249-40D1-B16B-7B3C1CA600C0 Q36186193-F5BBA178-2F52-49D7-83D3-C04DD036C50D Q38351134-2F60BCCA-D79A-4FBE-9E40-0C570BF2F5DD Q41018872-B3F99CC2-EA04-41B7-83C9-6670A0F45FD1 Q54252199-CA994FDE-234F-4A41-A25D-191906BBFE3B

P2860

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

http://www.wikidata.org/entity/Q34268618

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@ast

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@en

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@nl

type

label

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@ast

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@en

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@nl

prefLabel

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@ast

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@en

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@nl

P1433

Q34268618-4206EEF4-31A4-42E0-8169-6D97E94134C4

P1476

Q34268618-FA34B6A5-9CCB-42AE-9BE9-5EC273903975

P2093

Q34268618-5FE621ED-DA88-45DF-A7EE-3F0E931A61FF

Q34268618-F3E3D22D-541C-4B3B-B009-34A354E9EEBA

P2860

Q34268618-02671538-1FA3-43AE-9DF6-317AF277333D

Q34268618-0360EC72-8F4D-41B9-9481-D0D696EB4EC1

Q34268618-06169021-1A46-4BF4-B42B-509F2A99CD2A

Q34268618-0CD1C280-1F71-44F4-8F88-A03658DB1C24

Q34268618-0F396E92-DA8B-4EA1-A64D-8FA1CDD514AD

Q34268618-1044DCE5-1EC6-491B-9E6F-B240414A211F

Q34268618-133485DD-4F4F-4153-A6C9-ADF5C8F128A6

Q34268618-1365F9B9-B889-44EF-91B4-6AEE3ACE0CF4

Q34268618-171CFC6D-07DF-4D40-B3DC-86B3C1461553

Q34268618-175AA152-7178-406E-BF10-A9DE3095FC01

P2888

Q34268618-69F2C90A-FC11-4EAD-A060-E4A1375D2C8A

P304

Q34268618-BE5B4CDC-7595-4EEE-8AB3-A088FB1B0A0F

P31

Q34268618-D2DD83A5-2CCA-4F75-8B60-512D44D28F87

P356

Q34268618-20209787-71BB-4B48-A27E-BD39DAD9AFEF

P433

Q34268618-2E7D208F-4AFA-4F7A-A29D-5493738D9060

P478

Q34268618-6FBF2162-E11C-4D9A-BCF5-585C5B31EB24

P577

Q34268618-90C55E5C-B36E-485C-A89B-C5B7C40A4FC0

P5875

Q34268618-B99B65F9-014C-4DED-98D4-2CF0839D19C7

P6179

Q34268618-1A82E9B4-4FAE-4DBE-AD6C-EEC39351625F

P698

Q34268618-1FEAB53D-A060-439E-BD8E-6E177E6161CF

P932

Q34268618-73C1C186-2549-4BE7-8629-0FC275F1755A

P356

S12609-014-0155-Y

P1433

Current breast cancer reports

P1476

Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer

@en

P2093

Ciara C O'Sullivan

http://www.w3.org/2001/XMLSchema#string

Karen L Smith

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

P2888

s12609-014-0155-y

P304

169-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12609-014-0155-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266626691

http://www.w3.org/2001/XMLSchema#string

P6179

1047672363

http://www.w3.org/2001/XMLSchema#string

P698

25285186

http://www.w3.org/2001/XMLSchema#string

P932

4180403

http://www.w3.org/2001/XMLSchema#string